PillBot

The problem is that it is hard to have a quick look inside the stomach to understand why your tummy hurts.

Each year we spend $50B on endoscopes, yet we can only deliver an upper endoscopy (EGD) to 1% of humans in a modern care facility.

For the 1% who do get an EGD, they often report that it took five trips to the hospital before they even qualified for the procedure.

For ulcers, lesions, gastritis, and dozens of upper GI maladies, this is extremely frustrating.

For the millions of people who think that their stomach cancer is merely indigestion, this is terrifying.

PillBot is the world's first virtual endoscope (please watch that live demo!). It's a maneuverable robotic drone pill that uses three pumpjets to swim in 3D space in your stomach, after you drink a glass of water.

PillBot is a "moving eyeball in the stomach" that functions just like the tip of an endoscope, but over a telemedicine call from home, with zero capital equipment.

PillBot offers a continuous live video feed, and control can either be through a touchscreen app on the doctor's phone, or through a game controller.

PillBot is the fountain of data in the upper GI tract, both creating the AI tools that are so desperately needed, but also leveraging those tools for auto-scan features and more.

PillBot costs about $35 to build. Here's PillBot in action at Amazon MARS 2024:

PillBot serves people with stomachs who aren't feeling well, or who are curious to check on their upper GI health.

PillBot dematerializes hundreds of millions of physical hospital visits into telemedicine calls from home.

PillBot will allow gastroenterologists to use AI-enabled auto scanning protocols to drastically lower the amount of human effort required to investigate upper GI health.

PillBot is intended to make advanced upper GI healthcare 100x more affordable, and 100x more accessible, to everyone, everywhere.

PillBot frees up our hospitals and care facilities to treat advanced disease, by acting as the advanced scout out in the field.

Our Team Lead Torrey Smith has been designing medical devices for 18 years, and has experienced 3 exits in the medical device startup space.

Our core team includes world-leading gastroenterologists, a leader from GoogleX, and more than twenty crazy deep tech people from the SF Bay Area united to make PillBot a reality.

Endiatx is now 5 years old, having matured from a Silicon Valley garage startup to a professional organization now in clinical trials with our MVP.

Torrey's LinkedIn

Viv's LinkedIn

Mav's LinkedIn

Our clinical trials are underway in Auckland, New Zealand under approved IRB protocol. We had an amazing FDA pre-sub meeting in December confirming our Class 2 device status.

It is insane that our standard of care can only reach 1% of stomachs!

The extreme gatekeeping in upper GI care is largely related to the costs and risks associated with sedating a patient and jamming a tube down their throat in a hospital setting.

If we can bring better health technology to this space, in the form of PillBot, we believe that we can bring dignity and agency to every human being on (or off!) the Earth.

PillBot is innovative in that it is the first capsule that can be maneuvered in 3D flight inside the human stomach in a telemedicine-enabled manner.

PillBot moves under its own power with zero capital equipment.

In this way, we believe that PillBot is the world's first truly virtual endoscope.

This means that PillBot gives gastroenterologists the ability to actively investigate the inside of the human body from anywhere on (or off!) the planet.

PillBot costs $35 to make and it can dematerialize five trips to the hospital into a single video call from home in a typical use case.

In this way, we see a potential 100x improvement over the standard of care EGD, and all the gatekeeping associated with it.

We want to take a paradigm where 1% of stomachs can be investigated in a given year and make it trivial for anyone with a concern to rapidly access dignified 21st-Century healthcare.

We want advanced upper GI care to be 100x more affordable, and 100x more accessible.

PillBot through a basic telemedicine interface should be 10x better than the status quo in terms of cost and access.

PillBot with AI-enabled autoscanning features should be available without prescription, and should be 100x better.

PillBot is a multi-pumpjet swimming drone in the human stomach offering the functional optical tip of a typical endoscope without any hospital visit required.

We are currently in clinical trials under Cam Schauer in Auckland, New Zealand.

Our team has swallowed more than 60 PillBots in self-testing.

We've done a cadaver study at the Mayo Clinic.

We are sending more than 2 megapixels per second (480x480@10fps) of live video through our data link, and we are about to double the size of the image sensor and place a wide-angle lens on it.

PillBot is working and in clinical trials. We are using the clinical data to make the final tweaks. That includes placing and utilizing an inertial measurement unit (IMU).

15 full-time staff

11 part-time contractors

Endiatx is 5 years old. We incorporated as a Delaware c-corp on March 8th, 2019.

Please see slides 10 and 26 of our deck to see that our team is extremely diverse across gender, race, and other metrics.

Building robot pills has required an extremely diverse set of skill and life experience, and we are not surprised that the team that can make it happen mirrors that diversity.

We are a B2B RaaS (Robots as a Service) company that manufactures virtual endoscopic equipment for regulated sale to qualified medical professionals and facilities. Oure core customers are gastroenterologists and the hospitals and clinics that employ them.

AI-enabled auto-doc features will allow us to become a B2C business model as well, over the counter with no prescription becoming an option in time. This is an important growth market.

We've burned $6M in our 5 years, split evenly between early VC's and angel investors. We feel that our level of technical and clinical progress is approximately 10x more cash efficient than other medical robotics companies.

We are currently preparing for our Series A round to take us through FDA and to profitability in the open market.

We are exploring several exit scenarios, including an early sale to a Medtronic, a later sale to an Amazon, licensing core IP and staying a lean R&D company, an IPO, or simply remaining privately held and going the distance.